Teradyne Plunges on Conservative Guidance Despite Q1 Beat

What happened

Teradyne reported a record Q1 2026 with revenue of $1.282B, up 87% YoY, driven by AI-related demand which accounted for ~70% of sales. However, the stock dropped sharply after management guided Q2 revenue to $1.15B–$1.25B, down sequentially at the midpoint, disappointing investors who had priced in sustained momentum. The selloff reflects the market's realization that Q1's spike may be a pull-forward rather than the start of a durable upcycle, especially given management's lack of extended visibility beyond Q1. Customer concentration (top five at 44% of FY25 revenue) and the absence of order or backlog disclosures amplify uncertainty about future demand. The conservative guide, while prudent, validates the master report's WAIT rating: the stock needs to prove it can sustain a $1.2B+ quarterly run-rate before the premium multiple (P/E 107x) is justified.

Implication

The conservative guidance challenges the AI-driven growth narrative, making it prudent to wait for Q2 results (due late July) to confirm whether Q1 was an anomaly or a new baseline. A sustained revenue run-rate above $1.2B is needed to support the current valuation, while a miss or weak outlook would reinforce the bear case. Investors should monitor upstream capex signals from TSMC and memory makers, as well as any management disclosure on orders or backlog, as these will be critical to re-build conviction.

Thesis delta

The thesis shifts from cautious optimism to outright wait-and-see: while Q1 confirmed strong AI-driven demand, the downbeat Q2 guide and lack of order visibility underscore the lumpiness and concentration risks highlighted in the master report. The market's reaction confirms that the premium multiple requires tangible evidence of sustainable growth, not just a record quarter. The delta is that near-term risk has increased, making the attractive entry point of ~$300 more relevant and the re-assessment window tighter. Investors should not extrapolate Q1's run-rate without confirmation from Q2 results and Q3 guidance.